• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MGMT Gene Record

  • Summary
  • Interactions
  • Claims
  • MGMT 4255 Druggable GenomeClinically Actionable

    Alternate Names:

    4255
    O-6-METHYLGUANINE-DNA METHYLTRANSFERASE
    MGMT
    156569
    7059
    ENSG00000170430
    OTTHUMG00000019261
    34
    PA239
    O-6-methylguanine-DNA-alkyltransferase
    T24587
    P16455
    Methylated-DNA--protein-cysteine methyltransferase

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (7 More Sources)

    Gene Categories: Category Details

    DNA REPAIR
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME

    Publications:

    Preuss et al., 1996, Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs., Int. J. Cancer
    Okamoto et al., 2002, O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives., Jpn. J. Cancer Res.
    Maki et al., 2005, Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines., Oral Oncol.
    Chen et al., 1994, O6-methylguanine-DNA methyltransferase in ovarian malignancy and its correlation with postoperative response to chemotherapy., Gynecol. Oncol.
    Fang et al., 2005, Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy., Clin. Cancer Res.
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Watanabe et al., 2011, O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma., Brain Tumor Pathol
    Kreth et al., 2011, O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation., PLoS ONE
    Chinot et al., 2007, Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide., J. Clin. Oncol.
    Rapkins et al., 2015, The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide., Neuro-oncology
    Hegi et al., 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma., N. Engl. J. Med.
    Barvaux et al., 2004, Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase., Mol. Cancer Ther.
    Herrlinger U et al., 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet
    von Wronski et al., 1994, Effect of 5-azacytidine on expression of the human DNA repair enzyme O6-methylguanine-DNA methyltransferase., Carcinogenesis
    Ma et al., Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy., Oncol. Rep.
    Zhu R et al., 2012, Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase., Bioorg Med Chem Lett
    Pauly GT et al., 2008, Substitution of aminomethyl at the meta-position enhances the inactivation of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine., J Med Chem
    Mirzayans et al., 1992, Cytotoxic and mutagenic effects of methylnitrosourea in two human fetal fibroblast strains differing in O6-methylguanine-DNA methyltransferase activity., Carcinogenesis
    Badawi, 1998, O6-methylguanine and O6-methylguanine-DNA [corrected] methyltransferase activity in tissues of BDF-1 mice treated with antiparasitic drugs., Toxicol. Lett.
    Kokkinakis et al., 1997, Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents., Cancer Res.
    Kuo et al., 2006, DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors., J. Pharmacol. Exp. Ther.
    Christmann et al., 2001, Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT., Int. J. Cancer
    Esteller et al., 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents., N. Engl. J. Med.
  • CHEMBL485756   MGMT

    Interaction Score: 9.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22932317 18973327


    Sources:
    DTC

  • FOTEMUSTINE   MGMT

    Interaction Score: 3.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11279615


    Sources:
    NCI

  • LOMUSTINE   MGMT

    Interaction Score: 3.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9393761 30782343


    Sources:
    NCI CIViC

  • EXATECAN MESYLATE   MGMT

    Interaction Score: 3.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11802813


    Sources:
    NCI

  • TEMOZOLOMIDE   MGMT

    Interaction Score: 1.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404 21331613 21365007 17442989 25910840 15758010 15486188 30782343


    Sources:
    NCI CIViC PharmGKB

  • 6-O-BENZYLGUANINE   MGMT

    Interaction Score: 1.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18973327 22932317


    Sources:
    DTC

  • MAFOSFAMIDE   MGMT

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8621235


    Sources:
    NCI

  • IRINOTECAN HYDROCHLORIDE   MGMT

    Interaction Score: 0.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11802813


    Sources:
    NCI

  • IFOSFAMIDE   MGMT

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8621235


    Sources:
    NCI

  • CARMUSTINE   MGMT

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11070098


    Sources:
    CIViC

  • CHLORAMBUCIL   MGMT

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8621235


    Sources:
    NCI

  • DACARBAZINE   MGMT

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12168066


    Sources:
    NCI

  • HYCANTHONE   MGMT

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9609323


    Sources:
    NCI

  • MELPHALAN   MGMT

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8621235


    Sources:
    NCI

  • THIOGUANINE   MGMT

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1638685


    Sources:
    NCI

  • AZACITIDINE   MGMT

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7511991


    Sources:
    NCI

  • CAMPTOTHECIN   MGMT

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16258022


    Sources:
    NCI

  • GENISTEIN   MGMT

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16203797


    Sources:
    NCI

  • CISPLATIN   MGMT

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16043385 8314134


    Sources:
    NCI

  • Ensembl: ENSG00000170430

    • Version: 101_38

    Alternate Names:
    MGMT Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: MGMT

    • Version: 18-August-2020

    Alternate Names:
    PA239 PharmGKB ID

    Gene Info:

    Publications:
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics

  • CIViC: MGMT

    • Version: 14-September-2020

    Alternate Names:
    4255 Entrez Gene ID
    34 CIViC Gene ID

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:
    Herrlinger U et al., 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet
    Rapkins et al., 2015, The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide., Neuro-oncology
    Hegi et al., 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma., N. Engl. J. Med.

  • NCI: MGMT

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Preuss et al., 1996, Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs., Int. J. Cancer
    Okamoto et al., 2002, O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives., Jpn. J. Cancer Res.
    Ma et al., Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy., Oncol. Rep.

  • DTC: MGMT

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Zhu R et al., 2012, Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase., Bioorg Med Chem Lett
    Pauly GT et al., 2008, Substitution of aminomethyl at the meta-position enhances the inactivation of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine., J Med Chem

  • HingoraniCasas: ENSG00000170430

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000170430 Gene Symbol
    MGMT Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Tempus: MGMT

    • Version: 11-November-2018

    Alternate Names:
    MGMT Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: O-6-methylguanine-DNA-alkyltransferase

    • Version: 2020.06.01

    Alternate Names:
    MGMT TTD Gene Abbreviation
    T24587 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: MGMT

    • Version: 01-February-2022

    Alternate Names:
    Methylated-DNA--protein-cysteine methyltransferase Gene Name
    P16455 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • ClearityFoundationBiomarkers: MGMT

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • GO: MGMT

    • Version: 01-February-2022

    Alternate Names:

    Gene Info:

    Gene Categories:
    DNA REPAIR

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21